Vitrolife AB (SE:VITR)
:VITR
Want to see SE:VITR full AI Analyst Report?
VITR Stock Chart & Stats
kr133.00
-kr3.40(-1.91%)
At close: 4:00 PM EST
kr133.00
-kr3.40(-1.91%)
Day’s Range― - ―
52-Week Rangekr84.60 - kr163.10
Previous CloseN/A
Volume81.91K
Average Volume (3M)92.36K
Market Cap
kr14.13B
Enterprise Valuekr14.82B
Total Cash (Recent Filing)kr886.00M
Total Debt (Recent Filing)kr1.58B
Price to Earnings (P/E)31.6
Beta0.40
Next Earnings
Jul 10, 2026EPS Estimate
0.95Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)0.74
Shares Outstanding135,447,190
10 Day Avg. Volume105,869
30 Day Avg. Volume92,365
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.35
Price to Sales (P/S)5.39
P/FCF Ratio50.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.98
Revenue Forecast (FY)kr3.48B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationVitrolife’s consistent positive operating cash flow and meaningful TTM free cash flow provide durable liquidity that supports investments, restructuring costs and the dividend. Cash resilience cushions earnings volatility and preserves operational flexibility over the next several quarters.
Low Leverage / Stable Balance SheetManageable leverage and a sub-1 net debt/EBITDA ratio give Vitrolife room to fund strategic initiatives and absorb shocks. This balance-sheet strength supports continued capital returns and funds commercial/IT investments without forcing distress asset sales or deep cuts to R&D.
Recurring Consumables & Technologies MomentumStrong adoption of EmbryoScope and share gains in consumables point to durable recurring revenue and higher attach rates. Equipment penetration drives follow-on consumable demand and cross-sell, improving revenue visibility and supporting mid-term sustainable top-line recovery.
Bears Say
Volatile Profitability & Revenue SoftnessRevenue declines and repeated swings to net losses indicate unstable earnings conversion despite healthy gross margins. This volatility erodes equity, complicates multi-quarter planning and raises execution risk for margin recovery even if top-line conditions normalize.
Material Currency HeadwindsSignificant FX moves have materially depressed reported sales and margins. Currency volatility can persist and distort performance comparisons, delaying genuine underlying recovery and forcing management to absorb translation effects that stress short-term profitability and planning.
Restructuring, Higher OpEx And Regional HeadwindsRestructuring charges, higher selling and IT costs and exits in Genetic Services create near-term margin drag and uncertainty over test-service revenue. These structural moves improve focus long-term but compress EBITDA and cash flow near term and risk slower recovery in affected regions.
Vitrolife AB News
VITR FAQ
What was Vitrolife AB’s price range in the past 12 months?
Vitrolife AB lowest stock price was kr84.60 and its highest was kr163.10 in the past 12 months.
What is Vitrolife AB’s market cap?
Vitrolife AB’s market cap is kr14.13B.
When is Vitrolife AB’s upcoming earnings report date?
Vitrolife AB’s upcoming earnings report date is Jul 10, 2026 which is in 71 days.
How were Vitrolife AB’s earnings last quarter?
Vitrolife AB released its earnings results on Apr 23, 2026. The company reported kr0.74 earnings per share for the quarter, missing the consensus estimate of kr0.773 by -kr0.033.
Is Vitrolife AB overvalued?
According to Wall Street analysts Vitrolife AB’s price is currently Overvalued.
Does Vitrolife AB pay dividends?
Vitrolife AB pays a Annually dividend of kr1.1 which represents an annual dividend yield of 0.8%. See more information on Vitrolife AB dividends here
What is Vitrolife AB’s EPS estimate?
Vitrolife AB’s EPS estimate is 0.95.
How many shares outstanding does Vitrolife AB have?
Vitrolife AB has 135,447,190 shares outstanding.
What happened to Vitrolife AB’s price movement after its last earnings report?
Vitrolife AB reported an EPS of kr0.74 in its last earnings report, missing expectations of kr0.773. Following the earnings report the stock price went up 12.266%.
Which hedge fund is a major shareholder of Vitrolife AB?
Currently, no hedge funds are holding shares in SE:VITR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vitrolife AB
Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.
Technical Analysis
Getinge
―
BICO Group AB Class B
―
CellaVision AB
―
Xvivo Perfusion AB
―
Sectra AB Class B
―
Options Prices
Currently, No data available
---